Royalty Pharma

Extracted Attributes

Royalty Pharma

Royalty Pharma is a private equity investor firm founded in 1996. It purchases the rights to royalties on future drug sales. It claims to own partial rights to 7 of the top 30 selling drugs in the United States. As of 2026, it is valued at $26.1 billion (£19.3 billion).

Web Search Results

• Royalty Pharma Strategy and Business Model

  Royalty Pharma is a specialist biopharma-finance company that acquires royalty interests and provides royalty-based funding to universities, research hospitals, disease foundations, biotechnology companies, and pharmaceutical companies. Founded in 1996 by Pablo Legorreta and run from New York, with a U.K. plc domicile, Royalty Pharma sits between capital markets and the drug industry. It does not discover, manufacture, or market medicines itself. Instead, it buys rights to a portion of future sales from approved or late-stage therapies and then collects cash when partners commercialize those products globally. That makes its economics closer to specialty finance and intellectual-property investing than to a traditional pharmaceutical manufacturer. Its portfolio includes royalty interests [...] Acquisition of royalties on marketed medicines: This is the core business. Royalty Pharma buys rights to future cash flows tied to approved products with established commercial partners and observable sales trajectories. Acquisition of development-stage royalty rights: The company also invests in assets that are in clinical development or approaching launch, accepting more risk in exchange for potentially longer duration and stronger growth. Synthetic royalties and structured funding: Royalty Pharma can provide capital to biotech companies in exchange for a royalty-like economic interest, creating a non-dilutive financing tool for counterparties. [...] The main constraints are competition for attractive assets, patent-expiry timelines, clinical and regulatory risk on development-stage products, interest-rate sensitivity in valuation, and the possibility that a few large products continue to dominate cash flow for longer than management would prefer. ## 14. What Is the History of Royalty Pharma? Royalty Pharma was founded in 1996 by Pablo Legorreta to build a business around acquiring pharmaceutical royalty interests, a niche that was far less institutionalized at the time than it is today. Over the following decades, the company helped develop the market for monetizing royalties generated by academic research, biotechnology innovation, and pharmaceutical licensing.

• Royalty Pharma

  Description: Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing [...] future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, among others, and 19 development-stage product candidates. [...] - 2025-06-24: Royalty Pharma is excited to announce a $2 billion funding agreement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and up to $750 million senior secured loan. Daraxonrasib is a potential practice-changing medicine in Phase 3 development for RAS mutant pancreatic and...

• Royalty Pharma - Wikipedia

  Royalty Pharma was founded in 1996 by Pablo Legorreta. Legorreta came to the idea of the company in the early 1990s when while working as a mergers banker at Lazard Frères, he saw a 1987 investment by wealthy clients of PaineWebber in a chemotherapy drug. From this, he realized that drug royalties held major potential. in 1996, he left Lazard and with Rory Riggs, a former PaineWebber banker, raised $60 million to start what would later become Royalty Pharma. Instead of making bets on early stage drug development, Royalty usually buys rights to royalties on regulator approved drugs or drugs that are promising. It buys rights from the patent holders, typically a predetermined percentage of revenue from the new drug after it enters the marketplace. The owners of the rights, usually [...] American biopharmaceutical company Royalty Pharma | Type | Public | | Traded as | Nasdaq: RPRX | | Industry | Biopharmaceuticals | | Founded | 1996 | | Founder | Pablo Legorreta | | Headquarters | New York City, United States | | Revenue | Increase US$2.38 billion (2025) | | Net income | Decrease US$771 million (2025) | | Website | www.royaltypharma.com | Royalty Pharma is a private equity investor firm founded in 1996. It purchases the rights to royalties on future drug sales. It claims to own partial rights to 7 of the top 30 selling drugs in the United States. As of 2026, it is valued at $26.1 billion (£19.3 billion). ## History [edit] [...] In 2014, Royalty purchased the royalty rights to drugs developed with the financial support of the Cystic Fibrosis Foundation (CFF) for $3.3 billion. The payment covered the foundation's share of revenue from drugs like Kalydeco, which was developed by Vertex Pharmaceuticals with funding from the foundation. The deal was the largest royalty purchase ever made by Royalty. According to The New York Times, at the time it was believed to be "the largest financial return ever achieved for a charitable organization pursuing treatments for disease." The deal raised money which the CFF will use to fund its efforts as part of a venture philanthropy model. The firm went public in June 2020. ## References [edit]

• Royalty Pharma reports first quarter 2026 results | Royalty Pharma

  Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s [...] “Royalty Pharma has delivered a strong start to 2026 across multiple dimensions. We grew Royalty Receipts by 13% and announced up to $1.25 billion of royalty transactions in the first quarter,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “Importantly, we continue to innovate our business and are very excited by the emergence of a significant opportunity in R&D co-funding with global biopharma companies. Our transactions this year included two such agreements – with Johnson & Johnson and Teva – underscoring the growing demand for this novel funding modality. We were also delighted by positive clinical and regulatory developments across our portfolio, notably the unprecedented overall survival benefit for daraxonrasib in pancreatic cancer. [...] Image 4 2025 Corporate Responsibility Report News Accelerating Bio-Innovation Conference Search Search Close Search Panel # Royalty Pharma reports first quarter 2026 results Earnings 6 May 2026 Download PDF Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, NY, May 6, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.

• Royalty Pharma | Portfolio, Investments & AUM

  Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the life sciences industry.

• Country

  United States

• Founder

  Rory Riggs

• Instance Of

  Q4830453

• Headquarters

  New York City